Here is a valid rebuttal, when biotech stock gets FDA approval, they always jump by 50-100%+ (depending the product, IMO, RAP is such a product and there will be at least 100% spike) so why would they sell when after the approval, the revenue will be worth at least $100M+ and with minimal operating cost and expenditure of probably less than $5M (if that), let alone the patent IP by itself will also be worth at least $200-300M+ you would think?
Hence, over time, RAP will be a billion dollar company.
Yes some might sell some of those escrow shares but this will be soaked up as there is less risk associated with RAP being a billion dollar company over time after FDA approval but like I said, the good result from the FDA clinical trials and FDA approval isn't a given and market is trading it as such. If it was a given, most will be putting their house on it right now, even you....wouldn't you?
Telehealth on the rise, page-141
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #